Headache News and Research

Latest Headache News and Research

Migraine attacks leading to a Chinese accent in a British woman

In a bizarre incident a British woman after repeated attacks of migraine headache has started speaking with a Chinese accent. Sarah Colwill, 35, according to experts is suffering from a condition known as Foreign Accent Syndrome (FAS).

20 Apr 2010

"Brain Port" surgery helps remove colloid cyst in 15-week pregnant woman

A unique device developed to make brain surgery easier and less traumatic has been successfully used on a patient who was pregnant and suffering from a potentially life-threatening brain cyst. The device, called a "Brain Port," was pioneered by renowned neurosurgeon Amin Kassam, MD, Medical Director of the Neuroscience Institute at Saint John's Health Center.

19 Apr 2010

Study shows beneficial impact of TYSABRI on QoL in MS patients

Biogen Idec and Elan Corporation, plc today announced results from a one-year, longitudinal health outcomes studys 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

17 Apr 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune, Inc. today announced results of all three cohorts from a 15-day Phase 1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically infected with hepatitis C virus (HCV) genotype-1.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has entered into a Cooperative Research and Development Agreement with the Naval Medical Research Center. NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria.

16 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

52% migraine sufferers found relief from headache with Aspirin: review

Nearly 9 million people in UK suffer from debilitating headaches called migraine and this leads to a severe impairment in quality of life and affects productivity. The headaches associated with an attack may last for several days often bringing nausea and a general feeling of uneasiness in presence of lights and sounds.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

Aspirin can reduce acute migraine attacks

A single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain within two hours, for more than half of people who take it. It also reduces any associated nausea, vomiting, and sensitivity to light or sound (photophobia or phonophobia).

15 Apr 2010

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) to the U.S. Food and Drug Administration (FDA) for approval as a treatment for opioid dependence. The company requested a priority review for its sNDA and if granted by the FDA, it would mean a six month review timeline.

13 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

People with no health insurance are less likely than the privately insured to receive proper treatment for their migraines, according to a study published in the April 13, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

13 Apr 2010